In high-risk patients without known significant atherosclerosis and with diabetes, evolocumab significantly reduced the risk of a first major cardiovascular event. The study found that evolocumab was effective in preventing cardiovascular events in these patient populations.
A clinical trial found that intensive cholesterol-lowering therapy reduced the risk of cardiovascular events by 31% in high-risk patients with diabetes. The treatment, evolocumab, lowered LDL-C levels by approximately 60%, and was well-tolerated.
A post hoc analysis found that tirzepatide was associated with a lower incidence of a broad composite cardiovascular and kidney endpoint. The study compared tirzepatide with dulaglutide in patients with diabetes and established cardiovascular disease.
A post hoc analysis of the Finerenone Trial reveals that sudden death in heart failure was often preceded by modest worsening of symptoms and declining quality of life. The study suggests limited specificity for sudden death among other modes of death, implying a complex trajectory before modes of death.
The EMPEROR-Preserved risk model demonstrated good performance in the FINEARTS-HF trial, showing that baseline risk does not modify the relative treatment effect of finerenone. Finerenone has been shown to have a significant benefit for heart failure patients.
The MOMENTUM study found that 27% of patients with resistant hypertension have hypercortisolism, a condition characterized by elevated cortisol levels. This finding suggests that hypercortisolism may be an underlying cause of resistant hypertension, which impacts nearly 10 million patients in the US.
A new trial found that using a microaxial flow pump before and during cardiac stenting procedures for high-risk heart attack patients with severe heart attacks did not reduce heart damage. The study, published in the Journal of the American College of Cardiology, also showed increased bleeding complications.